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Background: Sunitinib has shown single-agent activity in patients with previously treated metastatic breast cancer
(MBC). We investigated the safety of the combination of sunitinib and paclitaxel in an exploratory study of patients with
locally advanced or MBC.
Methods: Patients received oral sunitinib 25 mg/day (with escalation to 37.5 mg/day as tolerated) on a continuous
daily dosing schedule and paclitaxel 90 mg/m2 on days 1, 8, and 15 of each 28-day cycle. Study endpoints included
safety (primary endpoint), pharmacokinetics, and antitumor activity.
Results: Twenty-two patients were enrolled. The most frequent adverse events (AEs) were fatigue/asthenia (77%),
dysgeusia (68%), and diarrhea (64%). Grade 3 AEs included neutropenia (43%), fatigue/asthenia (27%), neuropathy
(18%), and diarrhea (14%). No drug–drug interaction was observed on the basis of pharmacokinetic analysis. Of 18
patients with measurable disease at baseline, 7 (38.9%) achieved objective responses (including 2 complete and 5
partial responses). Clinical responses were observed in three of nine patients with triple-negative receptor status
(estrogen receptor negative, progesterone receptor negative, and human epidermal growth factor receptor-2
negative).
Conclusions: These data indicate that sunitinib and paclitaxel in combination are well tolerated in patients with
locally advanced or MBC. No drug–drug interaction was detected and there was preliminary evidence of antitumor
activity.
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introduction
The contribution of angiogenesis to tumor development is
a subject of increasing importance to oncology. Tumor-
associated angiogenesis is in part controlled by signaling
through the vascular endothelial growth factor (VEGF) and
platelet-derived growth factor pathways. Activation of both of
these pathways is required for the development and growth of
all solid tumors, including breast cancer, and both play an
important role in the formation of metastases. Studies have
shown that vascular endothelial growth factor receptors
(VEGFRs) are often overexpressed in breast cancer [1, 2], and
that high levels of VEGF are predictive of poor survival and
poor response to treatment in advanced breast cancer [3].
Similarly, the overexpression of platelet-derived growth factor
receptors (PDGFRs) is common in breast cancer tumors and
may predict shortened survival and treatment failure in patients
with advanced disease [4].
As a direct consequence of the identification of antiangiogenic
targets such as VEGFR and PDGFR, novel agents have been
developed that inhibit these signaling pathways. Preclinical data
from studies using targeted agents have provided a viable
justification for their development in the clinic [5]. Several
clinical studies of targeted agents have been conducted in patients
with breast cancer and have shown early evidence of clinical
activity [6, 7]. In addition, three phase III clinical trials with the
anti-VEGF antibody bevacizumab, given in combination with
taxane therapy, have demonstrated that progression-free survival
in the combination was superior to taxane alone in the first-line
treatment of metastatic breast cancer (MBC) [8–10]. These data
provide proof of concept for the activity of anti-VEGF agents in
the treatment of breast cancer, and it has been suggested that
dual inhibition of both VEGFR and PDGFR may prove more
effective than inhibition of either target alone [11].
Sunitinib is an oral, multitargeted tyrosine kinase inhibitor of
VEGFR-1, -2, and -3, PDGFR-a and -b, stem-cell factor receptor
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(KIT), FMS-like tyrosine kinase 3 (FLT 3), colony-stimulating
factor 1 receptor (CSF-1R), and glial cell line-derived
neurotrophic factor receptor (RET) [12–17]. Sunitinib has
inhibited tumor growth in breast cancer models [12, 15, 18] and
preliminary evidence of single-agent activity was reported in
a phase II study of sunitinib in heavily pretreated patients with
MBC [objective response rate (ORR) 11%] [19]. When given with
chemotherapy, a reduction in the rate of tumor growth of human
breast cancer xenografts was observed in mice and a survival
benefit reported [12, 20]. As such, it has been hypothesized that
sunitinib will have superior clinical activity in breast cancer when
administered in combination with other anticancer treatments.
Here, we present data from an exploratory study of sunitinib
given in combination with paclitaxel to patients with locally
advanced or MBC. The study aimed to analyze the
pharmacokinetic profiles of sunitinib and paclitaxel when given
in combination and to assess the tolerability and preliminary
antitumor activity of the combination.
methods
study population
Female patients, aged ‡18 years, with unresectable breast cancer that was
locally recurrent or metastatic and not amenable to curative resection or
radiation with curative intent were recruited. All acute toxic effects of prior
therapy or surgical procedures were to be resolved to grade one or less
(except alopecia). Other inclusion criteria included adequate organ
function, as defined by hematology and blood chemistry, Eastern
Cooperative Oncology Group performance status of one or less, and the
provision of informed consent.
Exclusion criteria included prior chemotherapy for advanced disease
(hormonal therapy in the adjuvant and/or advanced disease setting was
allowed), prior adjuvant taxane therapy with relapse £12 months from the
last dose, and prior treatment with tyrosine kinase inhibitors, VEGF
inhibitors, or other inhibitors of angiogenesis, including sunitinib. Patients
with human epidermal growth factor receptor-2 (HER2)-positive disease
were excluded unless the patient had previously received trastuzumab.
Major surgery, radiotherapy, or systemic therapy within 3 weeks of the
start of treatment was not allowed, with the exception of palliative
radiotherapy to nontarget metastatic lesions. Comorbid conditions that
constituted exclusion from the study included uncontrolled hypertension
(>150/100 mmHg) or brain metastases, diagnosis of any second malignancy
within the last 3 years, cardiac conditions, and transient ischemic attack or
pulmonary embolus in the 12 months before study entry.
study design
This was an exploratory, nonrandomized study evaluating sunitinib [oral
continuous daily dosing (CDD) schedule] combined with paclitaxel (i.v.
weekly for 3 weeks then 1 week off treatment) in patients with locally
recurrent or MBC. Both drugs were administered in 4-week cycles for up to
1 year.
The primary endpoint was safety and toxicity. Secondary endpoints
included pharmacokinetic parameters of paclitaxel and sunitinib (and its
active metabolite SU12662), alone and coadministered and antitumor
activity of the paclitaxel and sunitinib combination.
The study was conducted in accordance with the International
Conference on Harmonisation Good Clinical Practice guidelines, the
Declaration of Helsinki, and applicable local regulatory requirements and
laws. The institutional review board or independent ethics committee of
each participating center approved the study protocol, and all patients
provided informed consent.
study treatments
Treatment was administered in 4-week cycles. Sunitinib 25 mg was
administered orally, once daily, on a CDD schedule. Patients completing
one cycle of treatment with minimal adverse effects could escalate their dose
of sunitinib to 37.5 mg/day in subsequent cycles. Patients experiencing
dose-limiting toxic effects (DLTs; defined as a grade 4 hematologic toxicity,
grade 3 non-hematologic toxicity excluding uncontrollable nausea or
vomiting, or need for dose modification) attributable to sunitinib were
permitted to have 1-week off-treatment periods, as required, to manage
toxicity. Patients with recurrent grade 3 or 4 adverse events (AEs) other
than neutropenia could receive a reduced dose of sunitinib (12.5 mg/day).
Paclitaxel was administered i.v. as a 1-h infusion weekly for 3 weeks
followed by 1 week off treatment, at a starting dose of 90 mg/m2/week. The
paclitaxel dose could be reduced to 65 mg/m2 in subsequent cycles on the
basis of tolerability. One dose could be missed in the case of grade 3 toxicity.
Paclitaxel could be discontinued at the discretion of the investigator. Patients
discontinuing one agent due to maximum benefit or unacceptable toxicity
could continue single-agent therapy with the remaining agent. Patients were
pretreated with standard medications before paclitaxel infusion.
Hematopoietic growth factors (granulocyte colony-stimulating factor) were
permitted after cycle 1 to maintain neutrophil counts >1500/ll.
assessments
Pharmacokinetic parameters for paclitaxel, sunitinib, SU12662, and total
drug (sunitinib + SU12662) were estimated when drugs were administered
alone and in combination.
Physical examination, cardiac function, and blood chemistry were
reassessed once per cycle. Hematology was assessed before each paclitaxel
dose. AEs were graded according to the National Cancer
Institute—Common Terminology Criteria for Adverse Events, version 3.0.
Follow-up assessments were carried out 28 days after the last dose of study
medication.
Tumor assessments were conducted every 8 weeks and evaluated
according to RECIST [21]. Objective responses included both complete
responses (CRs) and partial responses (PRs) that were confirmed at least 4
weeks after the response was initially documented. Patients with evaluable/
measurable disease at baseline were included in these analyses.
statistical methods
The sample size of 22 patients was determined on an empirical basis, based
upon prior experience with small sample sizes in phase I studies [22, 23].
This sample size was felt to be adequate to characterize the safety of
treatment for investigation in future trials. Descriptive statistics were used
to summarize patient characteristics, compliance, efficacy, safety, and
pharmacokinetic parameters.
Pharmacokinetic parameters were calculated by noncompartmental
analysis of concentration–time data using WinNonlin version 4.1.a. For
paired observations, dose corrections for maximum concentration (Cmax),
area under the curve (AUC), and plasma concentrations to the intended
dose were made.
results
patient population and disposition
Twenty-two patients were enrolled in the study; baseline
characteristics are shown in Table 1. All 22 patients were
included in the safety and pharmacokinetic analyses and all 22
received at least one dose of paclitaxel; 21 patients received at
least one dose of sunitinib. Eighteen patients (82%) discontinued
treatment. Of these, one discontinued following the
investigator’s assessment that the maximum benefit from
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paclitaxel had been achieved and another discontinued as
response was such that further resection of the lesion was
possible. Thirteen patients (59%) discontinued due to disease
progression: 1 patient due to an AE (chronic leg ulcer), 1 due to
withdrawal of consent, and 1 due to failure to meet eligibility
criteria (preexisting hyponatremia discovered before the first
dose of sunitinib). Four patients (18%) completed 1 year of
study treatment.
treatment summary
Patients received a median of six cycles of sunitinib (range
2–15) and five cycles of paclitaxel (range 1–14). The dose of
sunitinib was escalated to 37.5 mg in 14 of 21 (67%) patients
and was maintained at 25 mg or reduced to 12.5 mg in 7 of 21
(33%) patients. The dose of paclitaxel was reduced to 65 mg/m2
in 8 of 22 (36%) patients. At least one dose delay of sunitinib
and of paclitaxel was experienced by 13 of 22 (59%) patients.
safety
Adverse events are presented in Tables 2 and 3. The most
frequent non-hematologic AEs of any grade were fatigue/
asthenia (77%), dysgeusia (68%), and diarrhea (64%). Four
patients (18%) experienced grade 2 or 3 hypertension. Other
grade 3 non-hematologic events included fatigue/asthenia
(27%), neuropathy (18%), and diarrhea (14%). There was one
case of grade 4 pulmonary embolism and one case of grade 1
vaginal hemorrhage that were considered related to study
treatment. One DLT occurred (neutropenia), resulting in
a temporary reduction in the paclitaxel dose. No deaths
occurred on study.
Transient neutropenia was the most common hematologic
toxicity, occurring at grade 3/4 in 48% of patients. Neutrophil
counts routinely rebounded during treatment on the sunitinib
CDD schedule. No cases of neutropenic fever or infection were
reported.
pharmacokinetics
Plasma pharmacokinetic parameters and geometric mean ratios
for patients with paired observations for sunitinib and paclitaxel
following multiple dosing with sunitinib alone (25 or 37.5 mg)
and with paclitaxel (90 mg/m2) are summarized in Table 4.
Geometric mean ratios of Cmax and AUC24(area under the
plasma concentration–time curve from time 0 to 24 h after
dose) for sunitinib and Cmax, AUClast (AUC from time zero to
time of the last measurable concentration), and AUCN(area
under the plasma concentration–time curve from time zero to
infinity) for paclitaxel did not indicate clinically significant
changes in pharmacokinetic parameters when sunitinib or
paclitaxel were administered alone or in combination.
efficacy
Of 18 patients with measurable disease at baseline, two CRs
(11.1%) and five PRs (27.8%) were reported, resulting in an
overall ORR of 38.9%. Stable disease ‡6 months was observed
in five patients, three of whom had nonmeasurable disease (two
patients with bone only disease and one with bone lesions plus
pleural effusion). Responses were recorded in three of nine
patients with triple-negative [estrogen receptor (ER) negative,
progesterone receptor (PgR) negative, and HER2 negative]
receptor status. Median progression-free survival was 33 weeks
[15.6–not reached (NR)]. Median overall survival was 66.6
weeks (58.4–NR), with a 1-year survival rate of 84% (range
70%–100%).
discussion
Data from this exploratory study indicate that sunitinib given
in combination with paclitaxel has an acceptable safety profile
in patients with advanced breast cancer. No pharmacokinetic
drug–drug interaction was observed between paclitaxel and
sunitinib. The data also indicate that the combination has
clinical activity in this patient population.
The safety profile of the combination of sunitinib and
paclitaxel is similar to that of each agent given as
monotherapy [9, 19], as demonstrated by a lack of
unexpected AEs. Most AEs were mild to moderate and easily
Table 1. Patient baseline characteristics
Patient characteristics Patients (N = 22)
Age, years
Mean (SD) 58.1 (9.7)
Range 37–74
Gender, n (%)
Female 22 (100)
Race, n (%)
White 17 (77)
Black 5 (23)
Extent of disease, n (%)
Locally recurrent 2 (9)
Metastatic 20 (91)
Histology, n (%)
Ductal 17 (77)
Ductal + lobular 1 (4.5)
Lobular 3 (14)
Inflammatory 1 (4.5)
Receptor status, n (%)
ER (positive/negative) 13/9 (59/41)
PgR (positive/negative/unknown) 9/12/1 (41/55/4.5)
HER2 (positive/negative/unknown)a 1/20/1 (5/91/4.5)
Triple negativeb 9 (40.9)
Prior adjuvant chemotherapy (%) 63.6
Disease, n (%)
Measurable 18 (82)
Nonmeasurable 4 (18)
Location of disease, n (%)
Lymph node 12 (55)
Liver 8 (36)
Lung 7 (32)
Bone 13 (59)
ECOG performance status, n (%)
0 12 (55)
1 10 (45)
aHER2 measured by IHC3+ or FISH+.
bHER2 negative, ER negative, and PgR negative.
SD, standard deviation; ER, estrogen receptor; PgR, progesterone receptor;
HER2, human epidermal growth factor receptor-2; ECOG, Eastern
Cooperative Oncology Group.
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managed. The most frequently reported non-hematologic AEs
included fatigue, dysgeusia, and diarrhea, and the most
common grade 3 non-hematologic AEs were fatigue,
neuropathy, and diarrhea. Neuropathy is a known side-effect
of paclitaxel treatment; an incidence of 17%–21.6% has
previously been reported with paclitaxel monotherapy [9, 24],
similar to the rate observed in this study with the sunitinib
and paclitaxel combination (18%).
A significant level of hypertension may have been expected
following treatment that includes an anti-VEGF agent. In the
current trial, two patients (9%) experienced grade 3
hypertension. Hypertension, as well as bleeding and thrombotic
events, has previously been reported with the anti-VEGF agent
bevacizumab when combined with paclitaxel; grade 3
hypertension was reported in 53 of 365 (14.5%) patients who
received bevacizumab plus paclitaxel in the phase III
registration trial, while grade 3 thrombosis or embolism
occurred at an incidence of 1.6% and hemorrhage at 0.5% [9].
No severe (grade 3 or 4) bleeding events were reported in the
current study, although there was one occurrence of grade 1
vaginal hemorrhage. Bleeding events in the current study
appeared to be somewhat increased compared with these
Table 2. Non-hematologic adverse events reported by at least 15% of patients regardless of relationship to treatment
Adverse eventa Sunitinib and paclitaxel (N = 22)
Grade 1, n (%) Grade 2, n (%) Grade 3, n (%) Grade 4, n (%) Total, n (%)
Fatigue/asthenia 4 (18) 7 (32) 6 (27) 0 17 (77)
Dysgeusia 8 (36) 6 (27) 1 (4.5) 0 15 (68)
Diarrhea 6 (27) 5 (23) 3 (14) 0 14 (64)
Alopecia 8 (36) 5 (23) 0 0 13 (59)
Nausea 5 (23) 6 (27) 1 (4.5) 0 12 (55)
Vomiting 8 (36) 2 (9.1) 1 (4.5) 0 11 (50)
Rash 4 (18) 6 (27) 0 0 10 (45)
Neuropathy (peripheral and
peripheral sensory neuropathy)
1 (4.5) 4 (18.2) 4 (18.2) 0 9 (41)
Dyspepsia 3 (14) 4 (18) 2 (9.1) 0 9 (41)
Stomatitis 4 (18) 4 (18) 0 0 8 (36)
Anorexia 1 (4.5) 4 (18) 1 (4.5) 0 6 (27)
Hand–foot syndrome 2 (9.1) 2 (9.1) 2 (9.1) 0 6 (27)
Cough 4 (18) 2 (9.1) 0 0 6 (27)
Dyspnea 2 (9.1) 2 (9.1) 2 (9.1) 0 6 (27)
Mucosal inflammation 3 (14) 3 (14) 0 0 6 (27)
Insomnia 5 (23) 0 0 0 5 (23)
Epistaxis 3 (14) 1 (4.5) 1 (4.5) 0 5 (23)
Anxiety 3 (14) 1 (4.5) 0 0 4 (18)
Depression 3 (14) 1 (4.5) 0 0 4 (18)
Dizziness 2 (9.1) 1 (4.5) 1 (4.5) 0 4 (18)
Headache 4 (18) 0 0 0 4 (18)
Edema peripheral 2 (9.1) 1 (4.5) 1 (4.5) 0 4 (18)
Pruritus 4 (18) 0 0 0 4 (18)
Skin discoloration 4 (18) 0 0 0 4 (18)
Hypertension 0 2 (9.1) 2 (9.1) 0 4 (18)
aNational Cancer Institute—Common Terminology Criteria for Adverse Events version 3.0.
Table 3. Hematologic adverse events (laboratory abnormalities: worst grade by patient)
Sunitinib and paclitaxel (N = 21a)
Grade 1b, n (%) Grade 2b, n (%) Grade 3b, n (%) Grade 4b, n (%) Total, n (%)
Neutrophilsc 5 (24) 5 (24) 9 (43) 1 (4.8) 20 (95)
White blood cells 3 (14) 6 (29) 10 (48) 0 19 (91)
Lymphocytes 2 (9.5) 3 (14) 7 (33) 3 (14) 15 (71)
Hemoglobin 8 (38) 9 (43) 2 (10) 0 19 (91)
Platelets 7 (33) 0 0 0 7 (33)
aOne patient received treatment with paclitaxel only on study and was withdrawn due to ineligibility (G3 hyponatremia) before administration of sunitinib.
No hematologic data were collected.
bNational Cancer Institute—Common Terminology Criteria for Adverse Events version 3.0.
cNo cases of neutropenic infection or fever were reported.
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historical data. Epistaxis of any grade occurred in five (23%)
patients (grade 3 in one patient) and there was one occurrence
of treatment-related grade 1 vaginal hemorrhage. There was
one treatment-related thrombotic event reported (grade 4
pulmonary embolism).
The most commonly reported grade 3/4 hematologic AE was
neutropenia, occurring in 10 patients (47.8%). Growth factor
support to maintain dose intensity was administered to 16
patients (73%). Grade 3/4 neutropenia has previously been
reported at an incidence of 0.3%–11.5% with paclitaxel
monotherapy [9, 24]. Growth factor support was not permitted
during cycle 1 which allowed baseline levels of treatment-
related neutropenia to be determined. As sunitinib has inherent
myelosuppressive properties, the combined myelosuppressive
effects of both agents may explain the increased rate of
neutropenia in this study, compared with studies of single-
agent paclitaxel.
While the majority of patients experienced at least one dose
interruption due to AEs, only one of the 21 patients who
received sunitinib and paclitaxel discontinued treatment due
to an AE. This indicates that with growth factor support and
intermittent periods off treatment, the regimen is well
tolerated with few patients discontinuing due to toxicity. These
data are consistent with those recently reported from an
exploratory study in which sunitinib was administered with
docetaxel [22] and indicate that these drugs can be safely
coadministered at standard doses in the treatment of advanced
breast cancer.
While cross-trial comparisons are always limited, the
antitumor ORR of 38.9% observed in the current study
following addition of sunitinib to paclitaxel is similar to that
observed in a phase III, open-label, randomized trial of
bevacizumab plus paclitaxel for the first-line treatment of MBC
(36.9%) [9]. However, median overall survival in the current
study was 66.6 weeks (16 months), and lower than observed
with the combination of bevacizumab plus paclitaxel
(26.7 months) [9].
Clinical responses were observed in three of nine (33.3%)
patients with the triple-negative receptor phenotype (ER2,
PgR2, and HER22). Activity against triple-negative breast
cancer was also reported following treatment with sunitinib
monotherapy in a phase II study of heavily pretreated patients
with MBC who demonstrated a 15% response rate (3 of 20
patients) [19]. The activity of sunitinib in triple-negative breast
cancer is being further evaluated by testing sunitinib versus
standard of care in a phase II study (SUN 1077) of previously
treated patients.
In conclusion, the results of this study demonstrate that
sunitinib administered in combination with paclitaxel to
patients with advanced breast cancer is well tolerated without
any drug–drug interaction. Sunitinib continues to be evaluated
as a potential treatment of advanced breast cancer in
combination with chemotherapy and studies with sunitinib are
continuing in the neoadjuvant breast cancer setting. In January
2009, accrual completed to the phase III SUN 1064 study
examining the combination of sunitinib and docetaxel versus
Table 4. Summary of sunitinib and paclitaxel pharmacokinetic parameters following administration of sunitinib alone or in combination with paclitaxel
Dose (sunitinib/paclitaxel)/
analyte parameter
Sunitinib or paclitaxel alone
mean (CV%), median
Sunitinib + paclitaxel, mean
(CV%), median
Geometric mean ratio (90%
CI)
25 mg/90 mg/m2, n = 16a
Sunitinib Cycle 1 day 22 Cycle 1 day 15 Cycle 1 day 15/cycle 1 day 22
Cmax (ng/ml) 46.5 (40), 44.7 49.8 (40), 48.4 1.06 (0.81–1.40)
AUC24 (ngh/ml) 943 (42), 904 979 (41), 956 1.03 (0.78–1.36)
Paclitaxel Cycle 1 day 1 Cycle 1 day 15 Cycle 1 day 15/cycle 1 day 1
Cmax (ng/ml) 4080 (58), 3990 4910 (36), 5725 1.29 (0.92–1.81)
AUCN (ngh/ml) 6450 (26), 6289 7964 (24), 8180 1.24 (1.05–1.46)
t1/2 (h) 9.9 (34), 9.6 13.2 (35), 13.6 NA
CL (l/h) 27.3 (33), 24.7 22.0 (30), 20.0 0.81 (0.67–0.97)
37.5 mg/90 mg/m2, n = 8
Sunitinib Cycle 2 day 22b Cycle 2 day 15b Cycle 2 day 15/cycle 2 day 22
DC-Cmax (ng/ml) 48.1 (42), 50.9 52.7 (45), 58.1 1.03 (0.64–1.67)
DC-AUC24 (ngh/ml) 976 (43), 1009 972 (45), 991 0.97 (0.59–1.57)
Paclitaxel Cycle 1 day 1b Cycle 2 day 15b Cycle 2 day 15/cycle 1 day 1
Cmax (ng/ml) 3852 (41), 4570 4975 (51), 3752 1.29 (0.85–1.95)
AUCN (ngh/ml) 7766 (68), 5783 8737 (46), 6880 1.20 (0.82–1.74)
t1/2 (h) 9.7 (29), 9.6 12.6 (20), 12.5 NA
CL (l/h) 26.6 (50), 25.1 20.9 (35), 20.8 0.83 (0.56–1.23)
aPaired observations.
bIn three of eight patients, paclitaxel dose was reduced to 65 mg/m2 on cycle 2 day 15. For these patients, dose correction for Cmax, AUCs, and plasma
concentration to the intended dose was made.
CV, coefficient of variation; CI, confidence interval; Cmax, maximum concentration; AUC24, area under the plasma concentration–time curve from time 0 to
24 h after dose; AUCN, area under the plasma concentration–time curve from time zero to infinity; t1/2, terminal elimination half-life; NA, not applicable;
CL, total clearance; DC-Cmax, dose-corrected (i.e. reference dose: 25 mg) maximum concentration; DC-AUC24, dose-corrected (i.e. reference dose: 25 mg)
area under the plasma concentration–time curve from time 0 to 24 h after dose.
original article Annals of Oncology
1440 | Kozloff et al. Volume 21 |No. 7 | July 2010
docetaxel alone as first-line treatment of patients with advanced
breast cancer. In addition, enrollment to SUN 1099 completed
in February 2009. This is a phase III, second-line study of
sunitinib plus capecitabine versus capecitabine alone in patients
with advanced breast cancer. However, a phase III combination
study of sunitinib plus paclitaxel versus bevacizumab plus
paclitaxel (SUN 1094) was stopped in 2009 as interim analyses
showed the primary end point could not be met.
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